EUVIMEDEUVIMED entdecken
Crossref

TESAMORELIN AMONG GROWTH HORMONE SECRETAGOGUE PEPTIDES: A COMPARATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, VISCERAL FAT REDUCTION, ENDOCRINE SELECTIVITY, AND SAFETY

Luiz Felippe Mendes Caquetti

INTERNATIONAL BLEST SCIENTIFIC · 01.04.2026 · 2 (06)

DOI: 10.65671/tsj24068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift INTERNATIONAL BLEST SCIENTIFIC, online erschienen am 01.04.2026. Verfasst von Luiz Felippe Mendes Caquetti.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tesamorelin stands out among growth hormone secretagogues due to its selective mechanism of action through activation of the GHRH receptor, preserving the physiological dynamics of the somatotropic axis. This study aimed to comparatively analyze tesamorelin in relation to other GH secretagogues, considering mechanisms of action, clinical evidence, effects on visceral and hepatic fat, endocrine selectivity, and safety profile. This is a critical narrative review with a qualitative approach, based on randomized clinical trials, mechanistic studies, and regulatory documents. The findings indicate that tesamorelin consistently reduces visceral adipose tissue, with additional effects on hepatic fat, while preserving subcutaneous fat and maintaining controlled IGF-1 modulation. Compared to ghrelin receptor agonists and recombinant growth hormone, tesamorelin demonstrates greater metabolic selectivity and reduced interference with broader neuroendocrine pathways. Its safety profile is predictable and manageable under appropriate monitoring, although surveillance of IGF-1 levels and glycemic parameters remains necessary. It is concluded that the effectiveness of tesamorelin is related to the quality of hormonal stimulation and its adherence to physiological regulation, establishing it as a model of selective intervention in visceral adiposity modulation.

Zitieren

APA

Caquetti, L. F. M. (2026). TESAMORELIN AMONG GROWTH HORMONE SECRETAGOGUE PEPTIDES: A COMPARATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, VISCERAL FAT REDUCTION, ENDOCRINE SELECTIVITY, AND SAFETY. INTERNATIONAL BLEST SCIENTIFIC, 2(06). https://doi.org/10.65671/tsj24068

Vancouver

Caquetti LFM. TESAMORELIN AMONG GROWTH HORMONE SECRETAGOGUE PEPTIDES: A COMPARATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, VISCERAL FAT REDUCTION, ENDOCRINE SELECTIVITY, AND SAFETY. INTERNATIONAL BLEST SCIENTIFIC. 2026;2(06). doi:10.65671/tsj24068

BibTeX
@article{Caquetti2026,
  author = {Caquetti, Luiz Felippe Mendes},
  title = {TESAMORELIN AMONG GROWTH HORMONE SECRETAGOGUE PEPTIDES: A COMPARATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, VISCERAL FAT REDUCTION, ENDOCRINE SELECTIVITY, AND SAFETY},
  journal = {INTERNATIONAL BLEST SCIENTIFIC},
  year = {2026},
  volume = {2},
  number = {06},
  doi = {10.65671/tsj24068}
}
Kostenlos starten →